Purpose: This study was aimed to determine whether Tc-99m-hexakis-2methoxyisobutylisonitrile (MIBI) scintigraphy performed in the middle of preoperative chemotherapy has a prognostic value in patients with malignant bone and soft tissue tumors (MBST).
P reoperative chemotherapy is essential to improve the prognosis of the patients with malignant bone and soft tissue tumors (MBST). For the evaluation of tumor response to preoperative chemotherapy, several modalities have been used, including computed tomography (CT), dynamic magnetic resonance imaging (MRI), angiography, and radionuclide imaging. [1] [2] [3] [4] [5] Although tumor size can be well evaluated with CT and MRI, estimating residual tumor cell viability is somewhat difficult. The assessment of residual tumor cell viability is important to develop treatment strategy of limb-sparing surgery. 6 -9 Early prediction of the tumor response to preoperative chemotherapy would be beneficial to treatment planning. The histopathologic response to preoperative chemotherapy assessed after operation is known as a prognostic factor.
Tc-99m-hexakis-2-methoxyisobutylisonitrile (MIBI) has been used as a popular myocardial perfusion imaging agent in patients with coronary artery disease. Tc-99m-MIBI has also been recognized as a useful imaging agent for various tumors, including bone and soft tissue tumors. 10 It is valuable not only to detect various tumors but also to evaluate the tumor response to chemotherapy, including MBST. 11, 12 Several studies have shown the possibility that the change of the Tc-99m-MIBI uptake from pre-to postchemotherapy reflects chemotherapeutic effect in patients with bone sarcomas. 13, 14 The change of Tc-99m-MIBI uptake from prechemotherapy to middle course of preoperative chemotherapy has been proved to reflect histopathologic response to preoperative chemotherapy; 11, 12 therefore, the change of Tc-99m-MIBI uptake might be a prognostic factor like tumor size and existence of primary metastasis at the diagnosis. 15, 16 However, no published study has assessed the value of Tc-99m-MIBI scintigraphy as an indicator of prognosis in patients with MBST.
This study was aimed to determine whether the combination of Tc-99m-MIBI scintigraphy before and after the middle course of preoperative chemotherapy has a prognostic value.
MATERIALS AND METHODS

Patients
After institutional ethical committee approval and informed patient consent, 90 patients (63 males and 27 females; average age, 31.0 years; range, 5-74 years) with various malignant bone and soft tissue tumors (42 patients with bone tumors and 48 patients with soft tissue tumors), confirmed pathologically in specimens obtained by biopsy and/or resection after chemotherapy, and who were treated between May 1992 and December 2003 were recruited in this study. There were 32 osteosarcomas (including 1 extraosseous osteosarcoma); 15 malignant fibrous histiocytomas; 9 Ewing sarcomas; 7 rhabdomyosarcomas; 6 synovial sarcomas; 6 liposarcomas; 4 leiomyosarcomas; 2 clear cell sarcomas; 2 chondrosarcomas; 2 alveolar soft part sarcomas; 2 angiosarcomas; 2 spindle cell sarcomas; and 1 malignant schwannoma.
A total of 71 (79%) primary tumors were located in extremities, and 19 (21%) occurred in truncal sites.
Chemotherapy was done with caffeine-assisted chemotherapy. All patients received 5 cycles of preoperative intra-arterial chemotherapy at intervals of 2 to 3 weeks. In each chemotherapy cycle, cisplatin (120 mg/m 2 ) was continuously infused through an intra-arterial catheter for 1 to 2 hours, followed by a 48-hour continuous intra-arterial infusion of doxorubicin (60 mg/m 2 ), and a 72-hour intra-arterial infusion of caffeine. 8, 17 Patients underwent clinical evaluation and imaging studies, including radiography, CT, and MRI, for the assessment of primary tumor. They also underwent a chest CT and radionuclide wholebody bone scan to detect osseous metastases. Follow-up evaluation to detect local recurrence and metastasis consisted of radiography, CT, MRI, bone scan, and Tl-201 scan.
Tc-99m-MIBI Scintigraphy
The Tc-99m-MIBI scintigraphy was performed before preoperative chemotherapy and after the 3 cycles of preoperative chemotherapy in all 90 patients. Planar imaging was performed at 15 minutes after intravenous infusion of 600 to 740 MBq (16.2-20 mCi) of Tc-99m-MIBI, with a gamma camera equipped with a low-energy, high-resolution, parallel-hole collimator.
Image Analysis
Tc-99m-MIBI scintigraphy was evaluated quantitatively. A region of interest (ROI) was set manually on the whole lesion, and a symmetrical ROI was set on the contralateral normal area as a background. If it was difficult to delineate the lesion on the scintigraphic image, we referred to the CT or MR image. The uptake ratio (⌬UR) was then calculated by dividing the count density (average counts/pixel) of the lesion by that of the contralateral normal area.
In the analysis of the images obtained after the 3 cycles of preoperative chemotherapy, tumor ROI was newly set to cover the whole lesion as described earlier. Therefore, ROI size was changed depending on the size of the tumor. When the tumor uptake of the radionuclide disappeared completely, the same ROI delineated at prechemotherapy was applied to calculate the indices.
For the prediction of the chemotherapeutic effect, the percent reduction of ⌬UR was calculated as follows:
Ϫ post-middle course of chemotherapy UR)/ (prechemotherapy UR) Less than 30% and 30% or more ⌬UR were defined as poor and good response to chemotherapy, respectively, based on the previous study, which proved Tc-99m-MIBI imaging performed in the middle course of preoperative chemotherapy well predicted the final tumor histopathologic response to chemotherapy in patients with MBST. 11, 12 
Histopathologic Evaluation of Chemotherapeutic Effect
The histopathologic response to chemotherapy was determined based on the degree of necrosis in the largest slice of the resected tumor. Grade IV (100% necrosis) was considered complete response, and grade III (90%Ն to Ͻ100% necrosis) was considered partial response. Tumors showing grade II and I (Ͻ50% to Ͻ90% and Յ50% necrosis, respectively) were considered as no change. 18 Less than 90% and 90% or more necrosis were judged as poor and good response to chemotherapy, respectively.
Statistical Analysis
Prognostic values were determined using a statistical software package (JMP Statistical Discovery Software). Overall survival and disease-free survival were analyzed by the Kaplan-Meier method to clarify the time-dependent cumulative survival rate, and the curves were compared using the 2-sample log-rank test. P Ͻ 0.05 was considered statistically significant. Univariate and multivariate Cox proportional hazards regression analyses were used to identify predictors of overall survival and disease-free survival. Overall survival was defined as the time from the initial diagnosis to death from any cause. Disease-free survival was defined as the time from the surgical operation to metastasis, local recurrence, or death from any cause.
We examined the following factors for prognostic significance: sex, age (whether Ͼ40 years), site of the tumor (extremity or truncal site), tumor type (bone tumor or soft tissue tumor), metastasis at initial presentation, ⌬UR, histopathologic response, surgical margin, and Tc-99m-MIBI uptake ratios before chemotherapy and after chemotherapy.
RESULTS
Follow-up time ranged from 4 to 142 months, with an average follow-up of 52 months. At initial presentation, 21 patients (23%) had clinically detectable metastases (primary metastasis) and 69 patients (77%) did not have metastasis (absence of metastasis). Two patients with osteosarcoma refused surgical operation after preoperative chemotherapy. Therefore, they were excluded from analysis. All other 88 patients had limb-salvage surgery.
Final histopathologic types of MBST were high-grade malignant tumors in all 88 patients (100%). In histopathologic evaluation of the tumor response to preoperative chemotherapy, 39 showed good response and 49 showed poor response. Good and poor responses of Tc-99m-MIBI uptake change (⌬UR м30% and ⌬UR Ͻ30%, respectively) were concordant with histopathologic response to chemotherapy in 88% of the patients (Table 1 ). This concordance was 90% (36 of 40 patients) in bone tumors and 85% (41 of 48 patients) in soft tissue tumors. Eighty patients showed negative surgical margins, and 8 patients showed positive surgical margins. In all patients with positive surgical margins, postoperative histopathologic examination of the resected tumors demonstrated no change, and ⌬UR (%) showed poor response (Ͻ30%).
Kaplan-Meier analysis demonstrated that absence of metastasis was significantly associated with good overall survival in all patients, patients with bone tumor, and those with soft tissue tumor (P Ͻ 0.0001, P Ͻ 0. 0001, P ϭ 0. 0003, respectively) ( Fig. 1 ). Negative surgical margin was also associated with good survival in all patients, in patients with bone tumors, and in those with soft tissue tumors (P ϭ 0.0002, P ϭ 0.0025, P ϭ 0.026, respectively). ⌬UR м30% was also associated with good survival in all patients and patients with bone tumor (P ϭ 0.011 and P ϭ 0.047, respectively), but was marginally associated with good survival in those with soft tissue tumor (P ϭ 0.091) ( Fig. 2 ). Histopathologic good response was significantly associated with good overall survival in all patients (P ϭ 0.025), but association was marginal in patients ⌬UR indicates percent reduction of Tc-99m-MIBI uptake ratio from prechemotherapy to after 3 cycles of chemotherapy; B, bone tumor; S, soft-tissue tumor.
with bone tumor (P ϭ 0.067) and insignificant in those with soft tissue tumor (P ϭ 0.18) ( Fig. 3 ). Both Tc-99m-MIBI uptake ratios before chemotherapy and after the middle course of preoperative chemotherapy were not associated with prognosis in all patients and in both patients with bone tumor and soft tissue tumor (P Ͼ 0.4 in all groups of patients).
When analysis was restricted to patients without metastasis, ⌬UR м30% was significantly associated with good survival in all patients (P ϭ 0.0056) and in patients with bone tumor (P ϭ 0.005); however, association was insignificant in patients with soft tissue tumor (P ϭ 0.13) ( Fig. 4) . Similarly, histopathologic good response was associated with good survival in all patients (P ϭ 0.0025) and in patients with bone tumor (P ϭ 0.007) but not in those with soft tissue tumor (P ϭ 0.11) ( Fig. 5 ). Sex, age, and the site of the primary tumor were not associated with prognosis. Both Tc-99m-MIBI uptake ratios before chemotherapy and after chemotherapy were not associated with prognosis (P Ͼ 0.26 in all groups of patients).
FIGURE 1.
Kaplan-Meier curves of primary metastasis and overall survival with metastasis (solid line) and absence of metastasis (dashed line). A, In all patients, primary metastasis is associated with worse overall survival (P Ͻ 0.0001). B, In patients with bone tumor, primary metastasis is associated with worse overall survival, too (P Ͻ 0.0001). C, In patients with soft tissue tumor, primary metastasis is also associated with worse overall survival (P ϭ 0.0003).
FIGURE 2.
Kaplan-Meier curves of the percent reduction of Tc-99m-MIBI uptake ratio (⌬UR) and overall survival with ⌬UR Ͻ30% (solid line) and ⌬UR м30% (dashed line). A, In all patients with ⌬UR м30% is associated with good overall survival (P ϭ 0.011). B, In patients with bone tumor, ⌬URм30% is also associated with good overall survival (P ϭ 0.047). C, In patients with soft tissue tumor, ⌬UR м30% tended to be associated with good overall survival (P ϭ 0.091).
FIGURE 3.
Kaplan-Meier curves of the histopathologic response and overall survival with poor histopathologic response (solid line) and good histopathologic response (dashed line). A, In all patients, good histopathologic response is associated with good overall survival (P ϭ 0.025). B, In patients with bone tumor, good histopathologic response tended to be associated with good overall survival (P ϭ 0.067). C, In patients with soft tissue tumor, good histopathologic response is not associated with good overall survival (P ϭ 0.18).
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Prognostic Value of Tc-99m-MIBI As shown in Table 2 , several variables were significant predictors of overall survival at univariate analysis. Good outcome was associated with absence of metastasis in all patients and in both patients with bone tumor and soft tissue tumor (hazard ratio ͓HR͔: 5.1, 95% confidence interval ͓CI͔: 2.7-9.4, P Ͻ 0.0001; HR: 7.3, CI: 2.7-20, P ϭ 0.0001; HR: 4.2, CI: 1.7-9.7, P ϭ 0.0021, respectively). Negative surgical margin was associated with good prognosis in all patients and in patients with bone tumor, but tended to be associated in patients with soft tissue tumor (HR: 3.9, CI: 1.7-8.0, P ϭ 0.0030; HR: 4.8, CI: 1.3-14, P ϭ 0.019; HR: 3.2, CI: 0.91-8.6, P ϭ 0.067). Good response in Tc-99m-MIBI imaging (⌬UR м30%) was associated with good prognosis in all patients and patients with bone tumor, but tended to be associated in patients with soft tissue tumor (HR: 2.3, CI: 1.2-4.7, P ϭ 0.010; HR: 2.7, CI: 1.02-8.5, P ϭ 0.040; HR: 2.1, CI: 0.90 -5.5, P ϭ 0.088, respectively). Histopathologic good response was associated with good prognosis FIGURE 4. Kaplan-Meier curves of percent reduction of Tc-99m-MIBI uptake ratio (⌬UR) and overall survival with ⌬UR Ͻ30% (solid line) and ⌬UR м30% (dashed line) in patients without primary metastasis. A, In all patients, ⌬UR м30% is associated with good overall survival (P ϭ 0.0056). B, In patients with bone tumor, ⌬UR м30% is associated with good overall survival (P ϭ 0.005). C, In patients with soft tissue tumor, ⌬UR м30% is not associated with good overall survival (P ϭ 0.13).
FIGURE 5.
Kaplan-Meier curves of the histopathologic response and overall survival with poor histopathologic response (solid line) and good histopathologic response (dashed line) in patients without primary metastasis. A, In all patients, good histopathologic response is associated with good overall survival (P ϭ 0.0025). B, In patients with bone tumor, good histopathologic response tended to be associated with good overall survival (P ϭ 0.007). C, In patients with soft tissue tumor, good histopathologic response is not associated with good overall survival (P ϭ 0.11). in all patients (HR: 2.0, CI: 1.1-4.0, P ϭ 0.024) but tended to be associated in patients with bone tumor (HR: 2.3, CI: 0.93-6.3, P ϭ 0.071) and was insignificantly associated in patients with soft tissue tumor (HR: 1.8, CI: 0.78 -4.7, P ϭ 0.17). The degree of Tc-99m-MIBI uptake ratios before chemotherapy and after the middle course of preoperative chemotherapy did not have an association with prognosis in any group of patients. Multivariate analysis showed that primary metastasis was the most powerful independent predictor of a lethal clinical outcome in MBST and in both bone tumor and soft tissue tumor (HR: 4.9, CI: 2.6 -9.1, P Ͻ 0.0001; HR: 15, CI: 4.9 -53, P Ͻ 0.0001; HR: 3.7, CI: 1.5-8.9, P ϭ 0.0069, respectively). ⌬UR had a good long-term prognostic value in all patients and in patients with bone tumor (HR: 2.2, CI: 1.1-4.4, P ϭ 0.017; HR: 6.0, CI: 2.0 -22, P ϭ 0.0009, respectively), but not in those with soft tissue tumor (HR: 1.5, CI: 0.61-4.1, P ϭ 0.38).
Good disease-free survival by Kaplan-Meier analysis was associated with ⌬UR м30% in all patients (P ϭ 0.0093) and in patients with soft tissue tumor (P ϭ 0.017) but not in patients with bone tumor (P ϭ 0.19) ( Fig. 6 ). Good disease-free survival tended to associate with histopathologic good response in all patients (P ϭ 0.057) and patients with soft tissue tumor (P ϭ 0.051) (Fig. 7) . Both Tc-99m-MIBI uptake ratios before chemotherapy and after chemotherapy did not have an association with disease-free survival (P Ͼ 0.36 in any group of patients).
Representative cases of the patients with good and poor response by Tc-99m-MIBI imaging are shown in Figs. 8, 9 , respectively.
DISCUSSION
The present study demonstrated for the first time that the tumor response to preoperative chemotherapy, defined by the significant reduction of tumor Tc-99m-MIBI uptake from prechemotherapy to post-midcourse of preoperative chemotherapy (⌬UR м30%), was not only a predictor of histopathologic tumor response FIGURE 6. Kaplan-Meier curves of percent reduction of Tc-99m-MIBI uptake ratio (⌬UR) and disease-free survival after surgical operation with ⌬UR Ͻ30% (solid line) and ⌬UR м30% (dashed line). A, In all patients, ⌬UR м30% is associated with good disease-free survival (P ϭ 0.0093). B, In patients with bone tumor, ⌬UR м30% is not associated with good disease-free survival (P ϭ 0.19). C, In patients with soft tissue tumor, ⌬UR м30% is associated with good disease-free survival (P ϭ 0.017).
FIGURE 7.
Kaplan-Meier curves of the histopathologic response and disease-free survival with poor histopathologic response (solid line) and good histopathologic response (dashed line). A, In all patients, good histopathologic response tended to be associated with good disease-free survival (P ϭ 0.057). B, In patients with bone tumor, good histopathologic response is not associated with good disease-free survival (P ϭ 0.36). C, In patients with soft tissue tumor, good histopathologic response tended to be associated with good disease-free survival (P ϭ 0.051).
FIGURE 8.
Anterior Tc-99m-MIBI image in a patient with osteosarcoma of the right proximal humerus. High uptake of Tc-99m-MIBI in the tumor before preoperative chemotherapy (A) almost disappeared after 3 cycles of preoperative chemotherapy (⌬UR ϭ 43%) (B). After 5 cycles of chemotherapy, tumor resection was performed, and complete histopathologic response (100% necrosis) was observed. The patient is alive with no local recurrence or metastasis 9 years after chemotherapy and surgery.
Prognostic Value of Tc-99m-MIBI but also a significant prognostic factor in MBST. ⌬UR м30% was significantly associated with good overall survival in patients with bone tumor and was associated with good disease-free survival in patients with soft tissue tumor.
Recently, Tc-99m-MIBI scintigraphy has been used not only to assess tumor uptake at initial diagnosis but also to assess the effect of preoperative chemotherapy in patients with MBST, because it accumulates largely in mitochondria by its negative transmembrane potential, and the uptake depends on the cell viability and metabolic status. 19 Histologic response to preoperative chemotherapy has been recognized as an important prognostic indicator; therefore, it should be appreciated that, as a noninvasive surrogate marker of histologic response, Tc-99m-MIBI imaging can be used as a prognostic indicator.
Although MBST are generally chemosensitive tumors and their sensitivity depends on variable tumor subtypes, 20 -23 preoperative chemotherapy is thought to have benefits in improving local control rates and long-term survival by reducing local tumor aggressiveness, eradicating micrometastasis, and obtaining a safety margin before surgery. It has been proved that the histopathologic response to preoperative chemotherapy, defined as Ն90% tumor necrosis, is an important prognostic factor in MBST. However, histopathologic evaluation is not always absolutely perfect. Some discrepancies between histopathologic and scintigraphic responses might have arisen if viable cells were located at the peripheral part of tumor or scattered inhomogeneously in the necrotic tissue, because the histopathologic grade of tumor response to preoperative chemotherapy was not always evaluated based on the surveillance throughout the tumor but evaluated principally using the largest slice of the resected tumor. Radionuclide imaging reflects whole tumor viability as a tracer uptake and would compensate for the potential weakness in the histopathologic evaluation. Another limitation of the histologic response assessment is that it is possible only once and only after the completion of the series of the preoperative chemotherapy and surgical resection, usually after 10 to 15 weeks of initial chemotherapy. In the present study, Tc-99m-MIBI imaging was performed at the middle course of preoperative chemotherapy, indicating earlier availability of the information about tumor response to chemotherapy and prognosis.
Traditional radiographic methods to assess response to preoperative chemotherapy, such as CT and MR imaging, have been used to measure volume changes. 24, 25 However, volume change measurement is an insensitive method to determine chemotherapy responsiveness and prognosis. Both imaging methods, especially MRI, can evaluate various phenomena during tumor regression, such as necrosis, hemorrhage, development of granulation tissue, and fibrosis. 26 -29 For the direct assessment of tumor viability, dynamic contrast-enhanced MRI could be a more precise method, 30 because it can provide information about tissue perfusion, capillary permeability, and hence tumor viability. However, to our knowledge, there is no systematic study whether dynamic MRI has significant value for the assessment of tumor response to preoperative chemotherapy and potential prognostic value.
Unlike morphologic imaging modalities, F-18 FDG PET demonstrated good correlation between a reduction in tumor glucose metabolism after preoperative chemotherapy and necrosis rate in patients with osteosarcoma. [31] [32] [33] [34] [35] [36] [37] [38] It has been evaluated whether F-18 FDG PET can be a prognostic indicator in 31 patients with osteosarcoma, with median follow-up of 2.6 years. It has been shown that high maximum standardized uptake value (SUV) before and after the completion of preoperative chemotherapy had an association with worse progression-free survival, and postchemotherapy SUV had an association with overall mortality. 34 Another study with F-18 FDG PET in 40 patients with osteosarcoma demonstrated that only postchemotherapy SUV was associated with progression-free survival. 36 In both of the studies, the change of FDG uptake from preto postchemotherapy was not associated with prognosis. In 36 patients with Ewing sarcoma, postchemotherapy SUV and ratio of postchemotherapy SUV to prechemotherapy SUV were fairly concordant with histologic response, but only postchemotherapy SUV was associated with outcome. 37 In 46 patients with soft tissue sarcoma, change in SUV after chemotherapy was correlated with histologic change, disease recurrence, and overall survival. 38 On the other hand, in 14 patients with MBST, the pathologically determined degree of necrosis postchemotherapy was concordant with PETassessed European Organization for Research and Treatment of Cancer classification of response in 57.1% of the cases. A significant number of patients had discrepancies, which may be in part explained by chemotherapy-induced inflammation. 39 In the present study, both the degree of Tc-99m-MIBI uptake ratios before and after 3 cycles of preoperative chemotherapy did not have an association with prognosis, but the change of the Tc-99m-MIBI uptake from pre-to postchemotherapy was an indicator of the prognosis. These differences among the PET studies and Tc-99m-MIBI study might arise from the differences in patient selection and used tracer.
There are several clinical utilities of Tc-99m-MIBI imaging in the management of MBST. As a surrogate marker of histologic response, high ⌬UR in Tc-99m-MIBI imaging can identify the patients with good response to chemotherapy and permits less aggressive limb-sparing surgery. On the other hand, low ⌬UR may indicate the patients would have unfavorable histologic response during the midcourse of preoperative chemotherapy, leading to an alteration in the regimen of the subsequent chemotherapy or more aggressive surgery.
Although F-18 FDG PET may have several potential clinical merits, such as good ability to detect smaller lesions and distant metastasis, Tc-99m-MIBI has a practical advantage over F-18 FDG PET in daily practice because of its continuous availability as a kit-based agent with Mo-99-Tc-99m generator system. In addition, imaging with a gamma camera can be performed without fasting and can be free from the influence of the serum glucose level; the imaging cost also is low compared with PET. The spatial resolution FIGURE 9. Anterior Tc-99m-MIBI image in a patient with osteosarcoma of the right distal femur. High uptake of Tc-99m-MIBI in the tumor before preoperative chemotherapy (A) decreased slightly after 3 cycles of preoperative chemotherapy (⌬UR ϭ 21%) (B). After 5 cycles of chemotherapy, tumor resection was performed, and poor histopathologic response (necrosis Ͻ90%) was observed. The patient succumbed to the disease 29 months after chemotherapy and surgery.
of Tc-99m-MIBI imaging with a gamma camera was lower than that of F-18 FDG PET; however, this issue is not considered as a significant disadvantage because MBST is usually large enough for imaging and analysis.
When we analyzed bone and soft tissue tumors separately, the reduction of the tracer uptake was also associated with overall survival in bone tumors but only tended to be associated with prognosis in soft tissue tumors (P ϭ 0.091). On the other hand, the reduction of the tracer uptake was significantly associated with disease-free survival in patients with soft tissue tumors but not in patients with bone tumors (P ϭ 0.19). Further evaluation might be needed in a large number of patients.
As a marker of tumor viability, we used Tc-99m-MIBI uptake in the early image rather than uptake in the delayed image and retention rate in dual-phase images. Tc-99m-MIBI has been proven to be one of the substrate of P-glycoprotein, which is a product of the human multidrug resistance-related protein. 40, 41 It was also shown that delayed Tc-99m-MIBI uptake was related to P-glycoprotein expression, whereas early uptake was not, 24 and the early uptake was comparable with early Tl-201 uptake in patients with MBST. 11, 12 Therefore, Tc-99m-MIBI early uptake seems to reflect tumor viability more properly than delayed uptake and retention rate.
Preoperative chemotherapy was done with caffeine-assisted chemotherapy in this study because caffeine can safely enhance the cytocidal effects of anticancer drugs through its DNA repair-inhibiting effects. 8, 17 Although whether caffeine can directly change the uptake of Tc-99m-MIBI in vivo is not reported yet, in vitro study demonstrated that caffeine did not significantly alter Tc-99m-MIBI net cell uptake. 19 Therefore, caffeine may not directly influence the process of Tc-99m-MIBI accumulation.
